REGISTERED NUMBER: 08853095 (England and Wales)

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 JANUARY 2026

FOR

BIORESOLVE LIMITED

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

4

DIRECTOR:

Dr S Chatfield

REGISTERED OFFICE:

9 Winchester Park

Bromley

Kent

BR2 0PY

REGISTERED NUMBER:

08853095 (England and Wales)

ACCOUNTANTS:

Sargeant Partnership Limited

Chartered Accountants

5 White Oak Square

London Road

Swanley

Kent

BR8 7AG

FIXED ASSETS

Tangible assets

4

536

714

CURRENT ASSETS

Debtors

5

1,218

9,700

Cash at bank

670

894

1,888

10,594

CREDITORS

Amounts falling due within one year

6

1,755

6,741

NET CURRENT ASSETS

133

3,853

TOTAL ASSETS LESS CURRENT LIABILITIES

669

4,567

PROVISIONS FOR LIABILITIES

134

179

NET ASSETS

535

4,388

CAPITAL AND RESERVES

Called up share capital

7

400

400

Retained earnings

8

135

3,988

SHAREHOLDERS' FUNDS

535

4,388

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 January 2026.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 January 2026 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 2 June 2026 and were signed by:

Dr S Chatfield - Director

1.	STATUTORY INFORMATION

Bioresolve Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates and other sales taxes. Turnover consists of the provision of services and is recognised upon provision of service.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Computer equipment

-

25% per annum on reducing balance

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2025 - 1 ) .

4.	TANGIBLE FIXED ASSETS

Computer

equipment

£

COST

At 1 February 2025

and 31 January 2026

1,791

DEPRECIATION

At 1 February 2025

1,077

Charge for year

178

At 31 January 2026

1,255

NET BOOK VALUE

At 31 January 2026

536

At 31 January 2025

714

5.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2026

2025

£

£

Trade debtors

-

4,800

Other debtors

1,218

4,900

1,218

9,700

6.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2026

2025

£

£

Taxation and social security

1,055

4,767

Other creditors

700

1,974

1,755

6,741

7.	CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:

Class:

Nominal

2026

2025

value:

£

£

100

Ordinary

£1

100

100

100

A Ordinary

£1

100

100

100

B Ordinary

£1

100

100

100

C Ordinary

£1

100

100

400

400

8.

RESERVES

Retained

earnings

£

At 1 February 2025

3,988

Profit for the year

4,147

Dividends

(8,000

)

At 31 January 2026

135

9.	DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

At the balance sheet date the Director Dr S Chatfield owed the company £1,218 (2025: £470).

10.	RELATED PARTY DISCLOSURES

During the year dividends of £8,000 were paid to Mrs L Chatfield.

11.	ULTIMATE CONTROLLING PARTY